In a series of 381 patients who received for low-risk prostate cancer, Beard et al. reported that the 5-year prostate-specific antigen (PSA) failure-free survival rate was 50% versus 80% in patients with and without PNI in their needle biopsy specimens, respectively (Beard et al., 2004). The gene discussed is KLK3; the disease is prostate carcinoma.